513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Luveltamab Tazevibulin Ovarian Cancer	Sutro Biopharma, Inc.	P2/3	D (26)
Nanrilkefusp Alfa Ovarian Cancer	SOTIO Biotech AG	P2	D (26)
NKG2D CAR-NK Ovarian Cancer	Hangzhou Cheetah Cell Therapeutics Co., Ltd	N/A	D (26)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Ovarian Cancer	University Health Network, Toronto	N/A	D (26)
sy001 Ovarian Cancer	Cell Origin Biotech (Hangzhou) Co., Ltd.	N/A	D (26)
ft538 Ovarian Cancer	Masonic Cancer Center, University of Minnesota	P1	D (24)
bi 3820768 Ovarian Cancer	Boehringer Ingelheim	P1	NR ()
Ckd-215 Ovarian Cancer	Chong Kun Dang Pharmaceutical	P1	NR ()
d215 Ovarian Cancer	Chong Kun Dang Pharmaceutical	P1	NR ()
Gtaexs617 Ovarian Cancer	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1/2	NR ()
IPH5301 Ovarian Cancer	Institut Paoli-Calmettes	P1	NR ()
Sapanisertib Ovarian Cancer	National Cancer Institute (NCI)	P1	NR ()
Wsk-Im02 Ovarian Cancer	WestVac Biopharma Co., Ltd.	P1	NR ()

Showing 501 to 513 of 513 assets

PreviousPage 11 of 11Next